Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.84B 3.35B 3.1B 2.9B 5.44B 362B 5.48B 36.79B 14.26B 178B 14.42B 14.11B 619B P/E 2026 *
16.1x
P/E 2027 * 13x
Enterprise Value 3.84B 3.35B 3.1B 2.9B 5.44B 362B 5.48B 36.79B 14.26B 178B 14.42B 14.11B 619B EV / Sales 2026 *
6.04x
EV / Sales 2027 * 5.35x
Free-Float
94.43%
Yield 2026 *
-
Yield 2027 * -
1 week+0.75%
Current month+1.89%
1 month+1.89%
3 months+42.07%
6 months+36.02%
Current year+33.53%
1 week 26.6
Extreme 26.6
27
1 month 26.4
Extreme 26.4
27
Current year 18.96
Extreme 18.965
27
1 year 16.15
Extreme 16.15
27
3 years 10.93
Extreme 10.93
27
5 years 4.12
Extreme 4.12
27
10 years 0.62
Extreme 0.621
27
Manager TitleAgeSince
Chief Executive Officer 65 2023-12-31
Director of Finance/CFO 55 2023-12-31
Chief Tech/Sci/R&D Officer 62 2025-05-31
Director TitleAgeSince
Chairman 78 2001-12-31
Director/Board Member 62 2002-09-30
Director/Board Member 65 2015-02-18
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.75% - - 3.84B
+0.33%-0.36%+19.66%-21.92% 62.05B
+0.20%-9.17%+58.54%+194.67% 54.52B
-3.92%+37.40%+37.40%+37.40% 41.55B
+7.62%+8.19%-51.58%-58.97% 39.06B
-1.05%-1.73%+54.74%-33.09% 29.02B
+3.50%+28.15%+146.95%-48.51% 25.38B
-0.78%-9.50%+43.47%+59.06% 19.62B
+1.74%-0.39%-1.99%+126.64% 16.89B
-0.05%+0.23%+61.48%+104.74% 15.89B
Average +0.76%+2.77%+40.96%+40.00% 33.78B
Weighted average by Cap. +0.77%+1.72%+36.40%+37.09%

Financials

2026 *2027 *
Net sales 636M 555M 514M 481M 902M 60.03B 907M 6.09B 2.36B 29.55B 2.39B 2.34B 103B 718M 626M 580M 543M 1.02B 67.74B 1.02B 6.88B 2.67B 33.34B 2.69B 2.64B 116B
Net income 231M 202M 187M 175M 328M 21.81B 330M 2.21B 858M 10.74B 868M 849M 37.28B 316M 276M 255M 239M 448M 29.84B 451M 3.03B 1.17B 14.69B 1.19B 1.16B 51B
Net Debt - -
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Date Price Change Volume
26-06-19 27.00 0.00% 0
26-06-18 27.00 +1.50% 0
26-06-17 26.60 -0.37% 0
26-06-16 26.70 -0.74% 0
26-06-15 26.90 +0.37% 0
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
31.38USD
Average target price
31.67USD
Spread / Average Target
+0.91%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!